Medtronic (NYSE:MDT) announced that it appointed Dr. Jeffrey Popma as its new VP and chief medical officer for coronary, renal denervation and structural heart business.

Popma, a professor of medicine at Harvard Medical School and director of interventional cardiology at Beth Israel Deaconess Medical Center in Boston, is slated to provide medical leadership across those businesses, serve as a strategic advisor for cardiovascular device innovation and help to develop a clinical research portfolio, according to a news release.

He is set to assume the role on June 22 and report to Nina Goodheart, president of the coronary & structural heart division as part of the cardiac and vascular group.

“I am honored to be joining Medtronic to help deliver on its enduring Mission of patient-focused medical device innovation,” Popma said in the release. “I look forward to collaborating with the talented cardiovascular and structural heart teams at Medtronic and listening to the guidance of their clinical advisors to help develop product solutions and clinical evidence strategies for the betterment of patients.

“I am also incredibly appreciative of the exceptional physicians and dedicated nurses who have supported me during my tenure at Beth Israel Deaconess Medical Center. I look forward to ongoing collaboration with these inspirational colleagues in the future.”

Popma previously served as president of the Society of Cardiac Angiography and Interventions and was chairman of the American College of Cardiology Cardiac Catheterization Committee. He has directed numerous cardiovascular device clinical trials over the last 20 years and has published more than 500 scientific articles in international peer-reviewed medical journals.

“We could not be more excited to welcome Dr. Popma to Medtronic,” Goodheart said. “Dr. Popma is a world-renowned clinical researcher and thought leader within the interventional cardiology space, and a long-time advisor and study investigator for Medtronic. We are honored that Jeff will bring his clinical, medical and scientific knowledge and expertise to CSH to help us further the Medtronic mission.”